Displaying items by tag: division of clinical immunology and rheumatology

A new study determines the cardiovascular safety of specific medications used to treat patients with gout.
A UAB rheumatologist serves as the lead author on the American College of Rheumatology white paper.
Four multidisciplinary studies will focus on genetics and associated mechanisms of hyperuricemia gout, an inflammatory arthritis.
John Mountz, M.D., Ph.D., and W. Winn Chatham, M.D., will be recognized by the ACR for education, research and clinical contributions to the field.
Researchers study the mechanisms that prevent autoimmune diseases like rheumatoid arthritis, systemic lupus erythematosus or multiple sclerosis after an infection.
A UAB study suggests a new bone boosting drug is more effective than commonly used bone loss medications in preventing fractures in women with osteoporosis.
UAB has created new clinical space with a $10 million renovation of the Whitaker Clinic at UAB Hospital.
The August issue of the journal focused on genomics in rheumatic diseases, the complex effort to understand the genetic underpinnings of more than 100 diseases that affect joints and muscles.
The Rheumatology Research Foundation’s Journey to Cure campaign funds eight rheumatology opportunities at the University of Alabama at Birmingham.
Following hip fracture increases after a reduction in reimbursement rates for DXA scans led to fewer scans, a UAB physician joined other advocates and successfully lobbied to increase DXA scan reimbursements to better identify and reduce hip fractures.
John D. Mountz, M.D., Ph.D., and Jasvinder A. Singh, M.D., have been awarded prestigious rheumatology awards for advances in basic and clinical research.
The National Osteoporosis Foundation has named leading rheumatologist Ken Saag from UAB as president of the group’s Board of Trustees.
UAB has implemented a new application suite to improve clinical trial management, and enhance communication among trial sites and with study participants.
A quality-control checkpoint in pre-B cells restricts the range of antibodies produced by mature B cells, and manipulation of the checkpoint could make vaccines more potent.
Page 3 of 5